18000 doses a day in anz, page-111

That's all well and good, but you should also be prepared for periodic disappointment when the reality of results announcements clash with overly optimistic expectations.

Dhukka, I've been trading and investing in shares for over 20 years. I am very well versed in the art of peridoic disappointment.

mak, the beauty of your analysis is you can come up with any value you like, your only constraints are to the extent to which you can extrapolate ever more positive outcomes.

Again, as usual, you misunderstand my point. Mastitis is an issue that, if POHs solution, does what it purports to do, will revolutionise treatment. It's not the sort of product (in comparison to the cosmetic offerings presented thus far) that is going to get 5% marketshare. IF the product does what it purports to, then I have no doubt that it is well worth it's current marketcap of $90mill and I am being very conservative.

Just to avoid confusion about what I am saying (and any possibilty of any strawman analogies) and to measure what I am saying, I expect that within a year of commercialisation (and probably sooner) that, if POHs product works, the marketcap of POH would be well above its current marketcap on this product alone.

Scepticism is easily overcome when a product actually works. It's hard to overcome when it doesn't, especially when we're dealing with such a prolific and costly problem.